What are the possible adverse reactions of using Milizumab?

Milikizumab(Mirikizumab) is a humanized monoclonal antibody that belongs to the IL-23 inhibitor class of drugs. It is mainly used to treat immune-mediated inflammatory diseases, such as moderate to severe ulcerative colitis. As a biological agent, militizumab reduces the inflammatory response by inhibiting the binding of IL-23 to its receptor, thereby alleviating the patient's clinical symptoms. However, like other biologics, militizumab may cause certain adverse reactions, and patients need to be carefully monitored during use.

Common adverse reactions of militizumab include infectious diseases, allergic reactions, injection site reactions, etc. One of the most common side effects is upper respiratory tract infection, in which patients may experience cough, sore throat, flu-like symptoms, etc. These infections are usually mild, but in some patients with weakened immune systems, they may pose a risk of more serious infections. Therefore, doctors often monitor patients for symptoms of infection while using militizumab, especially early in treatment.

Militizumab may also cause allergic reactions, with symptoms including rash, itching, and swelling of the face or throat. In some patients, a more severe allergic reaction such as anaphylactic shock, a life-threatening emergency, may occur. If a patient experiences a severe allergic reaction while taking the drug, he or she should stop taking the drug immediately and seek medical help.

Abnormal liver function is also one of the possible adverse reactions caused by militizumab. Studies have shown that some patients may experience elevated liver enzyme levels during the use of militizumab. Therefore, liver function needs to be checked regularly during treatment to ensure that the patient's liver health is not affected.

Additionally, although less common, some patients may experience gastrointestinal symptoms such as abdominal pain, nausea, or diarrhea. In most cases, these symptoms are mild and temporary, but if symptoms persist or worsen, adjustments to treatment should be considered.

Reference materials:https://omvoh.lilly.com/